Stifel Reiterates Bullish View on Kite Pharma (KITE) Following New Trial News

October 6, 2016 10:12 AM EDT
Get Alerts KITE Hot Sheet
Price: $47.10 -0.76%

Rating Summary:
    16 Buy, 2 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 11 | Down: 20 | New: 54
Trade KITE Now!
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.

Stifel analyst Thomas Shrader reiterated a Buy rating and $74 price target on Kite Pharma (NASDAQ: KITE) after the company announced this morning a new trial combining KTE-019 with Genentech’s anti-PD-L1 antibody atezolizumab.

Shrader commented, "This cost-shared trial will explore using an immuno-stimulatory signal to keep CAR-T cells active longer in patients. The trial will focus on chemo-refractory DLBCL patients rather than SCT relapsed DLBCL patients – a group that by all accounts, looks more difficult to treat. We expect this trial to be relatively exploratory with low doses tested first along with some experimentation as to when to add the immuno-stimulatory signal."

For an analyst ratings summary and ratings history on Kite Pharma click here. For more ratings news on Kite Pharma click here.

Shares of Kite Pharma closed at $56.41 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, FDA

Related Entities


Add Your Comment